Creatine supplementation in Parkinson disease: A placebo-controlled randomized pilot trial
Explore this paper's citation graph
Summary
Creatine improved patient mood and led to a smaller dose increase of dopaminergic therapy but had no effect on overall Unified Parkinson's Disease Rating Scale scores or dopamine transporter SPECT.
- Type
- dissertation
- Published
- 2006-10-10
- Cited by
- 206
- References
- 11
- OpenAlex
- https://openalex.org/W17030762
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:34241489
Keywords
Humanities, Philosophy
References
- Creatine and cyclocreatine attenuate MPTP neurotoxicity.
- The Role of Creatine in the Management of Amyotrophic Lateral Sclerosis and Other Neurodegenerative Disorders
- Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study
- Switching from ergot to nonergot dopamine agonists in Parkinson's disease: A clinical series and five‐drug dose conversion table
- Multinuclear magnetic resonance spectroscopy of high-energy phosphate metabolites in human brain following oral supplementation of creatine-monohydrate.
- The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease
- Mitochondrial dysfunction in bipolar disorder: evidence from magnetic resonance spectroscopy research
- Creatine supplementation lowers brain glutamate levels in Huntington’s disease
- A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease
- Neuroprotective agents for clinical trials in Parkinson’s disease: A systematic assessment
Cited by
- Clinical neuroprotection in Parkinson's disease - still waiting for the breakthrough.
- Use of creatine in the elderly and evidence for effects on cognitive function in young and old
- Literature-Related Discovery (LRD)
- Creatine protects against rotenone induced cell death of cerebellar granule neurons
- Role of the prolyl isomerase Pin1 in the pathogenesis of Parkinson's disease and neuroprotection by novel targeted compounds in pre-clinical animal models of the disease
- Perturbations du contrôle traductionnel et troubles cognitifs dans un modèle expérimental de la maladie de Parkinson : études de neuroprotection
- Can we prevent parkinson's disease?
- Iontophoretic delivery of selected antiparkinsonian agents in vitro
- Interventions that Improve Body and Brain Bioenergetics for Parkinson's Disease Risk Reduction and Therapy
- Multifunctional hits against Alzheimer's and Parkinson's diseases : screening for acetylcholinesterase and protein aggregation inhibitors
- Oxidative Stress in Neurodegenerative Diseases
- Homocysteine induces energy imbalance in rat skeletal muscle: Is creatine a protector?
- Creatine Supplementation and Exercise as Possible Therapeutic Treatments in Parkinson’s Disease: A Review.
- Creatine as a booster for human brain function. How might it work?
- Mitochondrial alterations in Parkinson’s disease: new clues
- Metabolite and Peptide Levels in Plasma and CSF Differentiating Healthy Controls from Patients with Newly Diagnosed Parkinson's Disease
- Creatine supplementation decreases plasma lipid peroxidation markers and enhances anaerobic performance in rats
- Creatine for women in pregnancy for neuroprotection of the fetus.
- Creatine as a neuroprotective agent in manganese-induced neurotoxicity
- The Phosphocreatine Circuit: Molecular and Cellular Physiology of Creatine Kinases, Sensitivity to Free Radicals, and Enhancement by Creatine Supplementation
Related papers
No related papers recorded.